



**KDDF**

Korea Drug Development Fund

# Introduction to KDDF


Korea Drug Development Fund



2022.Oct

# About KDDF

KDDF is a national consortium of three government ministries established in 2011 to foster innovation and, support the Korean biopharma companies to develop their pipelines via grants and various programs to promote international collaboration.



## What we have accomplished (2011~2020)



**1Bn(USD)**  
Investment Budget



**162**  
Accumulated Pipelines



**1**  
FDA and EMA approved drug



**3**  
MFDS\* approved drugs  
\*Ministry of Food & Drug Safety




**68**  
Licensing Deals



**18.7Bn(USD)**  
Biodollars Licensing Deals


# Licensing Activities



KDDF is collaborating with IPSCENT  
For the Global C&D Program

# Global C&D Program

Objective of the C&D program



# Global C&D Program

KDDF provides an “Open access platform”  
by searching, reviewing and presenting innovative pipelines




The Global Connection and Development (C&D) Program is a KDDF initiative program to promote global drug development by **introducing international assets to Korean companies.**

After introducing the assets, KDDF does not involve in any discussions held between the companies.

No success/match-making fees occurred from this program.


# Global C&D Program

## Procedure of the program



- ▶ Collecting from lead discovery/optimization to phase I
- ▶ Selecting assets fit to the Korean bio-industry via a member of reviewers
- ▶ Presenting mainly via C&D website and further promoting the program through a TECH-FAIR held in Seoul

# Highlights from previous Tech fairs



	1st TECH FAIR	2nd TECH FAIR	3rd TECH FAIR	4th TECH FAIR
Attendees	230	203	271	235
Partnering Meetings	28	28	67	74
Posters	30	40	30	32
Showcase Presentations	4	6	6	8

# C&D Website

GLOBAL C&D PROJECT









ABOUT PIPELINE TECH FAIR TECH FAIR HIGHLIGHTS LOGIN / JOIN / CONTACT US



TECH FAIR KDDF GLOBAL C&D PROJECTS TECH FAIR 2024

Overview Notice Program Venue Registration Partnering Schedule


PROGRAM HOME > TECH FAIR > PROGRAM

1<sup>st</sup> TECH FAIR 2<sup>nd</sup> TECH FAIR 3<sup>rd</sup> TECH FAIR 4<sup>th</sup> TECH FAIR

Time	Speaker Session	Parallel / Sessions
09:00 ~ 10:00	Registration	<ul style="list-style-type: none"> <li>Poster Session</li> <li>One-on-One Partnering</li> </ul>
10:00 ~ 10:05	Opening Remarks (KDDF CEO)	
10:05 ~ 10:10	Welcome Address (KDDF CBO)	
10:10 ~ 10:40	Showcase 1. ALBORADA DDI - Steve Andrews (Head of Chemistry)	<a href="#">Download</a> 
10:40 ~ 11:10	Showcase 2. Cancer Research UK - Matthew Burney (Business Development Manager)	<a href="#">Download</a> 
11:00 ~ 11:40	Showcase 3. Fraunhofer IZ - Thomas Trödel (Head of Business Development and Patent Management)	<a href="#">Download</a> 
11:40 ~ 12:10	Showcase 4. Lead Discovery Center - Sven Zittner (Business Development Manager)	<a href="#">Download</a> 
12:10 ~ 13:00	Lunch	
13:00 ~ 13:30	Showcase 5. Monash University - Kathy Nelson (Director, Commercialisation)	<a href="#">Download</a> 
13:30 ~ 14:00	Showcase 6. Oxford University Innovation - Richard Becher (Principal Learning & Ventures Manager)	<a href="#">Download</a> 
14:00 ~ 14:30	Showcase 7. Tufts University - Martin Sun (Senior Associate Director)	<a href="#">Download</a> 
14:30 ~ 15:00	Showcase 8. National Institutes of Health - Michael Segaller (Supervisor)	<a href="#">Download</a> 

4 <sup>th</sup> TECH FAIR				3 <sup>rd</sup> TECH FAIR				2 <sup>nd</sup> TECH FAIR				1 <sup>st</sup> TECH FAIR			
Time		Speaker Session				Parallel / Sessions									
09:00 ~ 10:00		Registration				<ul style="list-style-type: none"> <li>Poster Session</li> <li>One-on-One Partnering</li> </ul>									
10:00 ~ 10:05		Opening Remarks (KDDF CEO)													
10:05 ~ 10:10		Welcome Address (KDDF CBO)													
10:10 ~ 10:40		<b>Showcase 1. ALBORADA DDI</b> - Steve Andrews (Head of Chemistry)				<a href="#">Download</a> 									
10:40 ~ 11:10		<b>Showcase 2. Cancer Research UK</b> - Matthew Burney (Business Development Manager)				<a href="#">Download</a> 									





Overview Submission Pipeline List

### ASSET OVERVIEW

HOME > PIPELINE > PIPELINE LIST

**Number** 34

**Asset Name** (Duke Univ.) TAK1\_TNBC

**Main Therapeutic Area** Oncology Immunology

**Molecule Type** Small Molecule

**Development Stage** Lead Identification and Optimization

**Product Summary** The inventors developed novel synthetic TAK1 inhibitors that show exquisite selectivity against all other protein kinases for TAK1. Of these molecules is HS-206, a previously unreported TAK1 inhibitor that blocks TNF $\alpha$  dependent signaling. HS-206 shows high selectivity against TAK1 over all other known kinases expressed in the human genome (left). The inventors also have in vitro data demonstrating the inhibitory potency of HS-206 against TAK1, as well as its ability to be well tolerated in mice in studies of maximum tolerated dose. Finally, in cell-based assays, HS-206 potently inhibits cell proliferation of certain tumor lines, including triple negative breast cancer cells.

**Unmet needs / Market opportunity** Transforming growth factor b-activated kinase 1 (TAK1) plays a key role in the signaling pathways of inflammation and cell survival. TAK1 is activated by a number of pro-inflammatory signals (e.g., TNF $\alpha$ ), resulting in the induction of key inflammatory and pro-survival genes. TAK1 inhibition induces death of cancer cells and thus, TAK1 has emerged as a potential therapeutic target for cancer and inflammatory diseases. Despite the increasing interest in TAK1 as a potential therapeutic target, academia and industry alike have failed to develop selective small molecule inhibitors targeting TAK1. Previously identified inhibitors of TAK1 have not been advanced clinically, largely due to selectivity issues in vivo.

**FILE ATTACHMENTS**

(Duke Univ.) TAK1\_TNBC\_Teaser.pdf

(Duke Univ.) TAK1\_TNBC\_Research paper.pdf

(Duke Univ.) TAK1\_TNBC\_Patent.pdf

(Duke Univ.) TAK1\_TNBC\_Abstract.pdf

\* INTERESTED IN THIS ASSET? [INQUIRE HERE](#)

< Back

## Development Stage

Lead Identification and Optimization

## Product Summary

The inventors developed novel synthetic TAK1 inhibitors that show exquisite selectivity against all other protein kinases for TAK1. Of these molecules is HS-206: a previously unreported TAK1 inhibitor that blocks TNF $\alpha$  dependent signaling. HS-206 shows high selectivity against TAK1 over all other known kinases expressed in the human genome (left). The inventors also have in vitro data demonstrating the inhibitory potency of HS-206 against TAK1, as well as its ability to be well tolerated in mice in studies of maximum tolerated dose. Finally, in cell-based assays, HS-206 potently inhibits cell proliferation of certain tumor lines, including triple negative breast cancer cells.

## Unmet needs / Market opportunity

Transforming growth factor b-activated kinase 1 (TAK1) plays a key role in the signaling pathways of inflammation and cell survival. TAK1 is activated by a number of pro-inflammatory signals (e.g., TNF $\alpha$ ), resulting in the induction of key inflammatory and pro-survival genes. TAK1 inhibition induces death of cancer cells and thus, TAK1 has emerged as a potential therapeutic target for cancer and inflammatory diseases. Despite the increasing interest in TAK1 as a potential therapeutic target, academia and industry alike have failed to develop selective small molecule inhibitors targeting TAK1. Previously identified inhibitors of TAK1 have not been advanced clinically, largely due to selectivity issues in vivo.


## FILE ATTACHMENTS

(Duke Univ.) TAK1\_TNBC\_Teaser.pdf

(Duke Univ.) TAK1\_TNBC\_Research paper.pdf




# In-Licensing Highlights

Through the C&D Program, at least 4 projects have been in-licensed to Korean Pharmaceutical companies.



# Global C&D Project Participants

We introduced innovative pipelines of about 1,000 assets from over 400 institutions.



Thank you  
for your time



**KDDF**  
Korea Drug Development Fund